These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 11284774)

  • 21. Reduction of CD68+ macrophages and decreased IL-17 expression in intestinal mucosa of patients with inflammatory bowel disease strongly correlate with endoscopic response and mucosal healing following infliximab therapy.
    Caprioli F; Bosè F; Rossi RL; Petti L; Viganò C; Ciafardini C; Raeli L; Basilisco G; Ferrero S; Pagani M; Conte D; Altomare G; Monteleone G; Abrignani S; Reali E
    Inflamm Bowel Dis; 2013; 19(4):729-39. PubMed ID: 23448791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-TNF alpha: new therapy for Crohn's disease.
    Mikula CA
    Gastroenterol Nurs; 1999; 22(6):245-8. PubMed ID: 10855120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunoregulatory function of lamina propria T cells in Crohn's disease.
    James SP; Fiocchi C; Graeff AS; Strober W
    Gastroenterology; 1985 May; 88(5 Pt 1):1143-50. PubMed ID: 2858428
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T cell-B cell regulation in the intestinal lamina propria in Crohn's disease.
    Elson CO; Machelski E; Weiserbs DB
    Gastroenterology; 1985 Aug; 89(2):321-7. PubMed ID: 2861139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease.
    Danese S; Sans M; Scaldaferri F; Sgambato A; Rutella S; Cittadini A; Piqué JM; Panes J; Katz JA; Gasbarrini A; Fiocchi C
    J Immunol; 2006 Feb; 176(4):2617-24. PubMed ID: 16456024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease.
    Ringheanu M; Daum F; Markowitz J; Levine J; Katz S; Lin X; Silver J
    Inflamm Bowel Dis; 2004 Nov; 10(6):801-10. PubMed ID: 15626899
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of infliximab in the treatment of Crohn's disease in children and adolescents.
    Hyams JS; Markowitz J; Wyllie R
    J Pediatr; 2000 Aug; 137(2):192-6. PubMed ID: 10931411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Remicade does not abolish the need for surgery in fistulizing Crohn's disease.
    Poritz LS; Rowe WA; Koltun WA
    Dis Colon Rectum; 2002 Jun; 45(6):771-5. PubMed ID: 12072629
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn's disease.
    Nancey S; Blanvillain E; Parmentier B; Flourié B; Bayet C; Bienvenu J; Fabien N
    Inflamm Bowel Dis; 2005 Nov; 11(11):986-91. PubMed ID: 16239844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-TNF-α antibodies improve intestinal barrier function in Crohn's disease.
    Noth R; Stüber E; Häsler R; Nikolaus S; Kühbacher T; Hampe J; Bewig B; Schreiber S; Arlt A
    J Crohns Colitis; 2012 May; 6(4):464-9. PubMed ID: 22398062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro analysis of interferon gamma (IFN-gamma) and interleukin-12 (IL-12) production and their effects in ileal Crohn's disease.
    Colpaert S; Vastraelen K; Liu Z; Maerten P; Shen C; Penninckx F; Geboes K; Rutgeerts P; Ceuppens JL
    Eur Cytokine Netw; 2002; 13(4):431-7. PubMed ID: 12517728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infliximab for Crohn's disease.
    Verspaget HW; van der Zon AM; Gao Q; van Hogezand RA
    Aliment Pharmacol Ther; 2001 Dec; 15(12):2041-2. PubMed ID: 11736736
    [No Abstract]   [Full Text] [Related]  

  • 33. Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNFalpha antibodies (infliximab).
    Garcia-Planella E; Domènech E; Esteve-Comas M; Bernal I; Cabré E; Boix J; Gassull MA
    Eur J Gastroenterol Hepatol; 2003 Apr; 15(4):351-4. PubMed ID: 12655253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.
    Rutgeerts P; D'Haens G; Targan S; Vasiliauskas E; Hanauer SB; Present DH; Mayer L; Van Hogezand RA; Braakman T; DeWoody KL; Schaible TF; Van Deventer SJ
    Gastroenterology; 1999 Oct; 117(4):761-9. PubMed ID: 10500056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FOXP3+ regulatory T-cell counts correlate with histological response in Crohn's colitis treated with infliximab.
    Sloan S; Maxwell P; Salto-Tellez M; Loughrey MB
    Pathol Int; 2014 Dec; 64(12):624-7. PubMed ID: 25354875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and tolerability of repeated treatment with infliximab in patients with Crohn's disease: a retrospective data analysis in Germany.
    Witthöft T; Ludwig D
    Int J Colorectal Dis; 2005 Jan; 20(1):18-23. PubMed ID: 15459773
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evolution of cytokines and inflammatory biomarkers during infliximab induction therapy and the impact of inflammatory burden on primary response in patients with Crohn's disease.
    Billiet T; Cleynen I; Ballet V; Claes K; Princen F; Singh S; Ferrante M; Van Assche G; Gils A; Vermeire S
    Scand J Gastroenterol; 2017 Oct; 52(10):1086-1092. PubMed ID: 28622097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
    Baert F; Noman M; Vermeire S; Van Assche G; D' Haens G; Carbonez A; Rutgeerts P
    N Engl J Med; 2003 Feb; 348(7):601-8. PubMed ID: 12584368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q; Hogezand RA; Lamers CB; Verspaget HW
    Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Profiles of Lamina Propria T Helper Cell Subsets Discriminate Between Ulcerative Colitis and Crohn's Disease.
    Li J; Ueno A; Fort Gasia M; Luider J; Wang T; Hirota C; Jijon HB; Deane M; Tom M; Chan R; Barkema HW; Beck PL; Kaplan GG; Panaccione R; Qian J; Iacucci M; Gui X; Ghosh S
    Inflamm Bowel Dis; 2016 Aug; 22(8):1779-92. PubMed ID: 27243594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.